GSK plc 6-K, filed Dec 7, 2021
GSK plc (GSK)
6-K
2021-12-07
For: 2021-12-07
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on December 7, 2021.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of December 2021
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 7 December 2021, London UK and Quebec City,
Canada
Medicago and GSK announce positive Phase 3 efficacy and safety
results for adjuvanted plant-based COVID-19 vaccine
candidate
●Primary
endpoints and secondary endpoints for which data are available were
met in trial dominated by COVID-19 variants
●Efficacy demonstrated against all variants seen in
the study, including 75.3% efficacy against COVID-19 of any
severity caused by the globally dominant Delta
variant
●Vaccine
candidate was well-tolerated, with no related serious adverse
events reported in the vaccine group
●Final
regulatory submission to be filed with Health Canada
imminently
Medicago, a biopharmaceutical company headquartered in Quebec City,
and GlaxoSmithKline plc (GSK) today announce positive efficacy and
safety results from the global Phase 3 placebo-controlled efficacy
study of Medicago's plant-based COVID-19 vaccine candidate in
combination with GSK's pandemic adjuvant, conducted in over 24,000
subjects (adults 18 years and above) across six
countries.
Vaccine efficacy was demonstrated in an environment dominated by
SARS-CoV-2 variants, unlike most published Phase 3 efficacy
trials for currently licensed COVID-19 vaccines that were conducted
when only the ancestral virus was circulating, making direct
comparisons impossible. The overall vaccine efficacy rate against
all variants of SARS-COV-2 was 71% (95% CI: 58.7, 80.0; Per
Protocol Analysis: PP). The corresponding number for people
with an initial seronegative status indicating no previous exposure
to COVID-19 was 75.6% (95% CI: 64.2-83.7; PP). The vaccine
candidate demonstrated efficacy of 75.3% (95% CI: 52.8, 87.9; PP)
against COVID-19 of any severity for the globally dominant Delta
variant. Efficacy was 88.6% (95% CI: 74.6, 95.6; PP) against the
Gamma variant. Although only a small number of severe cases
occurred in this study, none occurred in the vaccinated group. No
cases of the Alpha, Lambda and Mu variants were observed in the
vaccinated group while 12 cases were observed in the placebo group.
The Omicron variant was not circulating during the
study.
During the study, no related serious adverse events were reported
and reactogenicity was generally mild to moderate and transient;
symptoms lasting on average only one to three days. To date, the
Phase 3 results have confirmed the safety profile is consistent
with Phase 2 results. The frequency of mild fever was low
(<10%), even after the second dose. Full results of the Phase 3
study will be released in a peer-reviewed publication as soon as
possible.
Based on these results, Medicago will imminently seek regulatory
approval from Health Canada as part of its rolling submission. The
vaccine candidate is not yet approved by any regulatory
authority.
"This is an incredible moment for Medicago and for novel vaccine
platforms. The results of our clinical trials show the power of
plant-based vaccine manufacturing technology. If approved, we will
be contributing to the world's fight against the COVID-19 pandemic
with the world's first plant-based vaccine for use in
humans," said Takashi Nagao, CEO and
President at Medicago. "I want
to thank everyone who participated in our clinical trials, our
collaborators at clinical trial sites, our partners at GSK, the
Government of Canada and Government of Quebec, all of our employees
and Mitsubishi Tanabe Pharma Corporation, for their commitment to
advancing vaccine science when the world needs
it."
Thomas Breuer, GSK's global COVID-19 adjuvanted vaccines lead and
Chief Global Health Officer, said, "These are encouraging results given data
were obtained in an environment with no ancestral virus
circulating. The global COVID-19 pandemic is continuing to show new
facets with the current dominance of the Delta variant, upcoming
Omicron, and other variants likely to follow. The combination of
GSK's established pandemic adjuvant with Medicago's plant-based
vaccine technology has significant potential to be an effective,
refrigerator-stable option to help protect people against
SARS-CoV-2."
Medicago has been developing its plant-based technology for the
past 20 years, using unique technology to produce Virus-Like
Particles (VLP) for its protein vaccines. VLPs are designed to
mimic the native structure of viruses, allowing them to be easily
recognised by the immune system. Because the VLPs lack core genetic
material, they are non-infectious and unable to replicate. VLP
vaccines developed by other technologies have traditionally been
used worldwide for more than 30 years.
"I am pleased to see our vaccine candidate moving forward and
bringing to the world the first plant-based vaccine against
COVID-19, diversifying the pool of vaccines available to help
improve public health and protect more people," said Yosuke Kimura,
Chief Scientific Officer at Medicago.
Medicago has initiated the regulatory filing process for the
adjuvanted plant-based COVID-19 vaccine candidate with the FDA (US)
and the MHRA (UK). Preliminary discussion is underway with the WHO
for preparation of the submission. Medicago has also initiated a
Phase 1/2 trial in Japan where it plans to submit for regulatory
approval in combination with the Phase 2/3 global study results
next spring.
About the Phase 2/3 study
The Phase 2/3 study has a multi-portion design to confirm that the
chosen formulation and dosing regimen of the vaccine candidate (two
doses of 3.75 µg of antigen combined with GSK's pandemic
adjuvant given 21 days apart) has an acceptable vaccine profile in
healthy adults 18-64 years of age, elderly subjects aged 65 and
over and adults with comorbidities.
The Phase 2 portion of the trial was a randomized, observer-blind,
placebo-controlled study to evaluate the safety and immunogenicity
of the adjuvanted recombinant COVID-19 plant-based vaccine
candidate in subjects aged 18 and above. It was conducted in
multiples sites in Canada and the United States in a population
composed of healthy adults (18-64y), elderly adults (over 65y) and
adults with comorbidities. Each age group enrolled up to 306
subjects randomized 5:1 to receive the adjuvanted vaccine
candidate: placebo and with 2:1 stratification in older adults
(65-74 and ≥75). All subjects are being followed for a period
of 12 months after the last vaccination for assessment of safety
and the durability of the immune responses which will be the final
analysis.
The Phase 3 portion of the trial was launched in March 2021 and was
an event-driven, randomized, observer-blinded, crossover
placebo-controlled design that evaluated the efficacy and safety of
the vaccine candidate formulation, compared to placebo, in over
24,000 subjects across Canada, the United States, United Kingdom,
Mexico, Argentina, and Brazil.
The data communicated are Per-Protocol, meaning only data from
participants who followed the protocol throughout the study are
included. A parallel Intention to Treat (ITT) analysis that
considers the treatment received by all participants, without
regard to protocol adherence yielded very similar
results.
The vaccination regimen calls for two doses (3.75 microgram of
antigen in combination with GSK's pandemic adjuvant) given
intramuscularly 21 days apart. The vaccine is stored at 2 °C
to 8 °C, enabling the use of traditional vaccine supply and
cold chain channels.
GSK commitment to tackling COVID-19
GSK's response to COVID-19 has been one of the broadest in the
industry, with potential treatments in addition to our vaccine
candidates in development with partner organisations.
GSK is collaborating with several organisations on COVID-19
vaccines by providing access to our adjuvant technology. We are
working with Sanofi, Medicago and SK bioscience
to develop adjuvanted, protein-based vaccines,
and all are now in Phase III clinical
trials. The use of an adjuvant can be of particular importance in a
pandemic since it may reduce the amount of vaccine protein required
per dose, allowing more vaccine doses to be produced and
contributing to protect more people in need.
GSK is also working with mRNA specialist, CureVac, to jointly
develop next generation, optimised mRNA vaccines for COVID-19 with
the potential to address multiple emerging variants in one
vaccine.
GSK is also exploring treatments for COVID-19 patients,
collaborating with Vir Biotechnology to investigate monoclonal
antibodies that could be used as therapeutic or preventive options
for COVID-19.
About Medicago
Medicago
is on a mission to improve global public health using the power of
plants. Founded in 1999 with the belief that innovative approaches
and rigorous research would bring new solutions in healthcare,
Medicago is a pioneer in plant-derived therapeutics. We are proudly
rooted in Quebec, with manufacturing capacity in both Canada and
the US. Our passionate and curious team of over 500 scientific
experts and employees are dedicated to using our technology to
provide rapid responses to emerging global health challenges, and
to advancing therapeutics against life-threatening diseases
worldwide.
Medicago
is an affiliated company of Mitsubishi Tanabe Pharma
Corporation.
For more information: www.medicago.com
About GSK
GSK is a science-led global healthcare company with a special
purpose: to help people do more, feel better, live longer. For
further information please visit www.gsk.com/about-us.
|
GSK enquiries:
|
|
|
|
|
Media enquiries:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Simon Moore
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Kristen Neese
|
+1 804 217 8147
|
(Philadelphia)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
|
|
|
|
Analyst/Investor enquiries:
|
Nick Stone
|
+44 (0) 7717 618834
|
(London)
|
|
|
Sonya Ghobrial
|
+44 (0) 7392 784784
|
(Consumer)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
|
Frannie DeFranco
|
+1 215 751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2020, GSK's Q3 Results and any
impacts of the COVID-19 pandemic.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: December
07, 2021
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|